Abstract: A process for the preparation on N-methyl-aryloxy-propanamine derivatives of the formula I and salts thereof. The invention also relates to the preparation and use novel intermediate of the formula XII. The invention also relates to the process of further conversion of novel intermediate into N-methyl-aryloxy propanamine derivatives and salts thereof. Wherein Q and P independently represents substituted or unsubstituted aryl group such as phenyl, naphthyl, pyridine, furanyl, pyranyl thienyl, and the like optionally substituted aryl by a halogen, a straight chain or branched alkyl group containing 1 to 6 carbon atoms, —O-alkyl group containing straight chain or branched C1-C6 alkyl group, an alkoxy group containing a straight chain or branched alkyl group having 1 to 6 carbon atoms, which comprises demethylation of N,N-dimethyl analogues of compound of formula IA.
Abstract: The present invention relates to an improved and commercially, viable process for the resolution of racemic cis milnacipran of formula I and its pharmaceutically acceptable salts of formula II. The present invention comprises using racemic cis milnacipran or its pharmaceutically acceptable salts as starting material, a low cost and commercially available resolving agent of formula III and industrially safe and economically low cost material such as water as a solvent. The said process results into optical isomers of racemic cis milnacipran having excellent optical purity without involving multiple crystallization steps. The present invention also comprises the concept of green chemistry as the invention works well with water as a solvent thereby minimizing the use of any other solvent.
Abstract: This invention concerns generally with a process for purifying crude pharmaceutical compositions, wherein the crude pharmaceutical composition comprises a sodium salt of Montelukast and more particularly relates to a process for the production of pharmaceutically pure preparations of Montelukast sodium using simulated moving bed technology, without requiring an intermediate acid formation step to separate isomers and to remove impurities.
Abstract: A process for isolating ?-anomer enriched Gemcitabine hydrochloride by converting Gemcitabine base into Gemcitabine hydrochloride followed by its purification using solvents from the series of water soluble ethers like 1,4-dioxane or Monoglyme.
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
June 5, 2012
Assignee:
Arch Pharmalabs Limited
Inventors:
Ashish Ujagare, Dattatrey Kochrekar, Matthew Uzagare
Abstract: A method for the preparation of 4-fluoro-?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzenebutanamide also known as 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid phenylamide of the formula I containing about 0.1% or less of ?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzene butanamide, about 0.05% or less of difluoro-?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzene butanamide and about 0.1% or less of 3-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethoxy]-4-methyl-pent-2-enoic acid phenylamide.
Type:
Grant
Filed:
November 11, 2010
Date of Patent:
April 24, 2012
Assignee:
Arch Pharmalabs Limited
Inventors:
Ganesh Gurpur Pai, K. Nanda Kishore, Narendra P. Chaudhari, N. Anjaneyulu, B. N. Ghogare
Abstract: Disclosed herein is a process for preparation of imatinib free base which comprises condensing 4-Methyl-N-(4-pyridin-3-yl-pyrimidin-2-yl)-benzene-1,3-diamine with 4-(4-Methyl-piperazin-1-ylmethyl)-benzoic acid ester in the presence of base including organic bases and inorganic bases in an organic solvent to form imatinib.
Abstract: A method for the preparation of 4-fluoro-?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzenebutanamide also known as 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid phenylamide of the formula I containing about 0.1% or less of ?-[2-methyl-1-oxopropyl]-?-oxo-N-p-diphenylbenzene butanamide, about 0.05% or less of difluoro-?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzene butanamide and about 0.1% or less of 3-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethoxy]-4-methyl-pent-2-enoic acid phenylamide.
Type:
Grant
Filed:
October 22, 2008
Date of Patent:
January 18, 2011
Assignee:
Arch Pharmalabs Limited
Inventors:
Ganesh Gurpur Pai, K. Nanda Kishore, Narendra P. Chaudhari, N. Anjaneyulu, B. N. Ghogare